Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

PPD Inc (PPD) USD0.01

Sell:$34.70 Buy:$34.80 Change: $0.32 (0.89%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.32 (0.89%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.32 (0.89%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

PPD, Inc. provides drug development services to the biopharmaceutical industry. The Company provides clinical development and laboratory services to pharmaceutical, biotechnology, medical device and government organizations, as well as other industry participants. The Company’s business segments include Clinical Development Services segment and Laboratory Services segment. Its Clinical Development Services offerings span the lifecycle of clinical product development and includes product development and consulting services, early development services, phases II-IV clinical trial management, accelerated enrollment solutions, peri- and post-approval services and medical communications. The Company’s Laboratory Services segment offers bioanalytical laboratory services, biomarker laboratory services, vaccine science services, good manufacturing practice (GMP) laboratory services and central laboratory services.

Contact details

929 North Front Street
United States
+1 (910) 2510081

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$11.75 billion
Shares in issue:
350.31 million
Life Sciences Tools & Services
United States
US dollar

Key personnel

  • David Simmons
    Chairman of the Board, Chief Executive Officer
  • Christopher Scully
    Chief Financial Officer, Executive Vice President, Treasurer, Assistant Secretary
  • William Sharbaugh
    Chief Operating Officer
  • Ronald Garrow
    Chief Human Resource Officer, Executive Vice President
  • B. Judd Hartman
    Executive Vice President, Chief Administrative Officer
  • Julia James
    Executive Vice President, General Counsel, Company Secretary
  • Christopher Fikry
    Executive Vice President - Global Laboratory Services
  • David Johnston
    Executive Vice President - Global Clinical Development
  • Karen Kaucic
    Executive Vice President and President of Evidera, Chief Medical Officer
  • Anshul Thakral
    Executive Vice President, Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.